Modulus Therapeutics
acquired by Ginkgo BioworksSeattle, US · Founded 2020 · Delaware corporation · 3 known investors
Find your way into Modulus Therapeutics
Sign up to see every warm intro you have to Modulus Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Modulus Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Ginkgo Bioworks April 2024 · terms undisclosed · source ↗
Modulus Therapeutics applies in-house gene editing, in vivo screening, multi-omics, and machine learning in an iterative design process to develop optimized cell therapeutics. The company aims to make its cell-therapy design approach scalable and repeatable across diseases and cell types.
Founders & leadership
Investors · 3
How we know: KdT Ventures's portfolio page · a partner's Signal profile · funding news · press coverage · the VCSheet dataset · Not right? Tell us
How we know: Madrona Venture Group's portfolio page · a partner's Signal profile · funding news · unite.ai · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$3.8M disclosed across 1 round · 2021
▶$3.8MraisedJul 2021 · 9 investors · BiotechnologyRule 506(b)
- Bryce R DainesExecutive Officer, Director
- Max C DarnellExecutive Officer, Director
- Offering amount
- $3.8M
- Amount sold
- $3.8M
- Minimum investment
- $125K
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Modulus Therapeutics do?
- Modulus Therapeutics applies in-house gene editing, in vivo screening, multi-omics, and machine learning in an iterative design process to develop optimized cell therapeutics. The company aims to make its cell-therapy design approach scalable and repeatable across diseases and cell types.
- Who are Modulus Therapeutics's investors?
- Modulus Therapeutics's investors include KdT Ventures, Madrona Venture Group.
- How much funding has Modulus Therapeutics raised?
- Modulus Therapeutics has disclosed $3.8M raised across 1 round.
- Who acquired Modulus Therapeutics?
- Modulus Therapeutics was acquired by Ginkgo Bioworks.
- Where is Modulus Therapeutics headquartered?
- Modulus Therapeutics is headquartered in Seattle, US.
